Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 3
2006 2
2007 2
2008 3
2009 4
2010 5
2011 6
2012 2
2013 5
2014 2
2015 4
2016 2
2017 2
2018 4
2019 6
2020 5
2021 4
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R, Descamps G, Bellanger C, Dousset C, Maïga S, Alberge JB, Derrien J, Cruard J, Minvielle S, Lilli NL, Godon C, Le Bris Y, Tessoulin B, Amiot M, Gomez-Bougie P, Touzeau C, Moreau P, Chiron D, Moreau-Aubry A, Pellat-Deceunynck C. Durand R, et al. Among authors: minvielle s. Blood. 2024 Mar 28;143(13):1242-1258. doi: 10.1182/blood.2023021581. Blood. 2024. PMID: 38096363
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation.
Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, Boinon R, Douillard E, Devic M, Magrangeas F, Moreau P, Minvielle S, Touzeau C, Letouzé E. Derrien J, et al. Among authors: minvielle s. Nat Cancer. 2023 Nov;4(11):1610. doi: 10.1038/s43018-023-00646-4. Nat Cancer. 2023. PMID: 37684528 No abstract available.
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation.
Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, Boinon R, Douillard E, Devic M, Magrangeas F, Moreau P, Minvielle S, Touzeau C, Letouzé E. Derrien J, et al. Among authors: minvielle s. Nat Cancer. 2023 Nov;4(11):1536-1543. doi: 10.1038/s43018-023-00625-9. Epub 2023 Aug 31. Nat Cancer. 2023. PMID: 37653140
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
Decombis S, Bellanger C, Le Bris Y, Madiot C, Jardine J, Santos JC, Boulet D, Dousset C, Menard A, Kervoelen C, Douillard E, Moreau P, Minvielle S, Moreau-Aubry A, Tessoulin B, Roue G, Bidère N, Le Gouill S, Pellat-Deceunynck C, Chiron D. Decombis S, et al. Among authors: minvielle s. Blood. 2023 Nov 2;142(18):1543-1555. doi: 10.1182/blood.2023020211. Blood. 2023. PMID: 37562004
Exploring the impact of dexamethasone on gene regulation in myeloma cells.
Bessonneau-Gaborit V, Cruard J, Guerin-Charbonnel C, Derrien J, Alberge JB, Douillard E, Devic M, Deshayes S, Campion L, Westermann F, Moreau P, Herrmann C, Bourdon J, Magrangeas F, Minvielle S. Bessonneau-Gaborit V, et al. Among authors: minvielle s. Life Sci Alliance. 2023 Jul 31;6(9):e202302195. doi: 10.26508/lsa.202302195. Print 2023 Sep. Life Sci Alliance. 2023. PMID: 37524526 Free PMC article.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC. Samur MK, et al. Among authors: minvielle s. Blood. 2023 Apr 6;141(14):1724-1736. doi: 10.1182/blood.2022017094. Blood. 2023. PMID: 36603186 Free PMC article.
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors.
Aktas Samur A, Fulciniti M, Avet-Loiseau H, Lopez MA, Derebail S, Corre J, Minvielle S, Magrangeas F, Moreau P, Anderson KC, Parmigiani G, Samur MK, Munshi NC. Aktas Samur A, et al. Among authors: minvielle s. Blood Cancer J. 2022 Dec 20;12(12):171. doi: 10.1038/s41408-022-00759-6. Blood Cancer J. 2022. PMID: 36535935 Free PMC article.
Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.
Alberge JB, Kraeber-Bodéré F, Jamet B, Touzeau C, Caillon H, Wuilleme S, Béné MC, Kampfenkel T, Sonneveld P, van Duin M, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Chérel M, Moreau P, Minvielle S, Bailly C. Alberge JB, et al. Among authors: minvielle s. J Nucl Med. 2022 Jul;63(7):1008-1013. doi: 10.2967/jnumed.121.262884. Epub 2022 Jan 27. J Nucl Med. 2022. PMID: 35086897 Free PMC article.
A polygenic risk score for multiple myeloma risk prediction.
Canzian F, Piredda C, Macauda A, Zawirska D, Andersen NF, Nagler A, Zaucha JM, Mazur G, Dumontet C, Wątek M, Jamroziak K, Sainz J, Várkonyi J, Butrym A, Beider K, Abildgaard N, Lesueur F, Dudziński M, Vangsted AJ, Pelosini M, Subocz E, Petrini M, Buda G, Raźny M, Gemignani F, Marques H, Orciuolo E, Kadar K, Jurczyszyn A, Druzd-Sitek A, Vogel U, Andersen V, Reis RM, Suska A, Avet-Loiseau H, Kruszewski M, Tomczak W, Rymko M, Minvielle S, Campa D. Canzian F, et al. Among authors: minvielle s. Eur J Hum Genet. 2022 Apr;30(4):474-479. doi: 10.1038/s41431-021-00986-8. Epub 2021 Nov 30. Eur J Hum Genet. 2022. PMID: 34845334 Free PMC article.
69 results